<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58723">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341534</url>
  </required_header>
  <id_info>
    <org_study_id>HS058</org_study_id>
    <nct_id>NCT02341534</nct_id>
  </id_info>
  <brief_title>BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction</brief_title>
  <acronym>BIO|GUARD-MI</acronym>
  <official_title>BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BIO|GUARD-MI study investigates whether continuous arrhythmia monitoring and the
      consequent treatment after detected arrhythmias in patients after acute myocardial
      infarction with preserved cardiac function, but other risk factors, decreases the risk of
      major adverse cardiac events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients randomized to the BioMonitor arm will receive an implantable cardiac monitor (ICM;
      BioMonitor) with remote monitoring function (Home Monitoring®). If the device detects and
      reports an arrhythmia, patients will be appropriately examined and treated. Patients
      randomized to the control arm will receive best proven treatment, but no implantable cardiac
      monitor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first major cardiac adverse event (MACE)</measure>
    <time_frame>From randomization until official study end or drop-out, patients will be followed and assessed for primary endpoint events and Time-to-Event Outcome Measures for an expected average of 4.0 years.</time_frame>
    <description>MACE is defined as death for cardiovascular reasons or unplanned hospitalisation for cardiovascular reasons.
The time period with regards to the Time-to-Event Outcome Measures starts with the randomization of the patient.
All patients will be assessed for Time-to-Event Outcome Measures until formal study termination is announced or until the individual patient meets a drop out criterion in accordance with the study protocol. The study period is estimated 6 years. Within the initial phase, 640 patients have to be enrolled within 2 years and followed for a further 4 years until the end of the clinical investigation. Within the second phase, 2260 patients have to be enrolled within 2 years and followed for a further 2 years until the end of the clinical investigation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2900</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>BioMonitor arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BioMonitor group (standard of care and implantation with investigational device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group (standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMonitor</intervention_name>
    <description>Patients will be implanted with the BioMonitor + standard of care</description>
    <arm_group_label>BioMonitor arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of AMI according to guidelines

          -  CHADS2-score ≥ 3 with modified age-variable ≥ 65 years

          -  LVEF &gt; 35 % as estimated by echocardiography within 6 months before enrollment but
             after conclusion of AMI treatment

          -  Patient accepts activation of Home Monitoring®

          -  Patient has provided written informed consent

        Exclusion Criteria:

          -  Platelet count &lt; 90.000 per mm3 or patients with haemorrhagic diathesis

          -  Permanent oral anticoagulation treatment for atrial fibrillation

          -  Indication for chronic renal dialysis

          -  Pacemaker or ICD implanted or indication for implantation

          -  Previously documented sustained VT

          -  Parkinson's disease

          -  Life expectancy &lt; 1 year

          -  Participation in another interventional clinical investigation

          -  Female patients who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jons, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet; Denmark; Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dietmar Bänsch, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Rostock University Hospital; Germany; Rostock</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Poul Erik Bloch Thomsen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Aalborg University Hospital, Denmark, Aalborg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Sogaard, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital, Denmark, Aalborg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sascha Mrosk</last_name>
    <phone>+49 (0) 30 68905-1308</phone>
    <email>bio-guard-mi@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnieszka Mucha</last_name>
    <phone>+49 (0) 30 68905-1326</phone>
    <email>bio-guard-mi@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg Universitetshospitel</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Würtemberg</state>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <state>Bavaria</state>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Humboldt-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 26, 2016</lastchanged_date>
  <firstreceived_date>December 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
